Previous 10 | Next 10 |
2023-09-14 08:54:47 ET More on Neurocrine Seeking Alpha’s Quant Rating on Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Eff...
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation PR Newswire Prescription Drug User Fee Act (PDUFA) Target Action Date Set for April 30, 2024 SAN DIEGO , Sept. 14, 2...
2023-09-12 14:05:37 ET More on Spruce Seeking Alpha’s Quant Rating on Spruce Biosciences Historical earnings data for Spruce Biosciences Financial information for Spruce Biosciences Spruce Biosciences: H2 2023 Data Could Be A Game Changer For CAH Treat...
2023-09-12 11:57:12 ET More on Neurocrine Seeking Alpha’s Quant Rating on Neurocrine Biosciences Historical earnings data for Neurocrine Biosciences Financial information for Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Ou...
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH) PR Newswire CAHtalyst ™ Met Primary Endpoint Demonstrating a Statistically Significant Decrease from ...
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditions NBI-1117570 is the second compound to advance into clinical development from a portfolio of selec...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults PR Newswire SAN DIEGO , Sept. 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Pha...
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September PR Newswire 2023 Wells Fargo Healthcare Conference on September 7 in Boston Morgan Stanley 21 st Annual Global Healthcare Conference on September 12 in New York ...
Neurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and Impact Following Treatment With INGREZZA® (valbenazine) Capsules PR Newswire ...
2023-08-28 10:50:19 ET More on Neurocrine Biosciences Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts BMO upgrades Neurocrine to market perform on ...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $170.00 for NBIX on 2024-07-12 08:10:00. The adjusted price target was set to $170.00. At the time of the announcement, NBIX was trading at $146.5. The overall price target consensus is at $...
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results PR Newswire Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasd...